Ocumension Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Ocumension Therapeutics is Victor Liu, benoemd in Aug2018, heeft een ambtstermijn van 6.25 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 5.94M, bestaande uit 71.5% salaris en 28.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.15% van de aandelen van het bedrijf, ter waarde HK$ 175.95M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5 jaar.

Belangrijke informatie

Victor Liu

Algemeen directeur

CN¥5.9m

Totale compensatie

Percentage CEO-salaris	71.5%
Dienstverband CEO	6.3yrs
Eigendom CEO	4.1%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

Analyse CEO-vergoeding

Hoe is Victor Liu's beloning veranderd ten opzichte van Ocumension Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥323m
Mar 31 2024	n/a	n/a	-CN¥351m
Dec 31 2023	CN¥6m	CN¥4m	-CN¥380m
Sep 30 2023	n/a	n/a	-CN¥399m
Jun 30 2023	n/a	n/a	-CN¥418m
Mar 31 2023	n/a	n/a	-CN¥411m
Dec 31 2022	CN¥5m	CN¥3m	-CN¥403m
Sep 30 2022	n/a	n/a	-CN¥393m
Jun 30 2022	n/a	n/a	-CN¥383m
Mar 31 2022	n/a	n/a	-CN¥322m
Dec 31 2021	CN¥5m	CN¥4m	-CN¥260m

Compensatie versus markt: De totale vergoeding ($USD 820.24K ) Victor } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 392.59K ).

Compensatie versus inkomsten: De vergoeding van Victor is gestegen terwijl het bedrijf verliesgevend is.

CEO

Victor Liu (53 yo)

6.3yrs

Tenure

CN¥5,943,000

Compensatie

Mr. Ye Liu, also known as Victor, serves as Chief Executive Officer at Ocumension Therapeutics since joining on August 1, 2018 and has been its Executive Director since November 23, 2018. Mr. Liu is respon...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ye Liu	CEO & Executive Director	6.3yrs	CN¥5.94m	4.15% HK$ 176.0m
Zhaopeng Hu	Chief Development Officer & Executive Director	4.4yrs	CN¥2.21m	0.46% HK$ 19.5m
Tim Ruan	CFO & Joint Company Secretary	1.8yrs	geen gegevens	geen gegevens
DongHong Chen	Chief Medical Officer	5.1yrs	geen gegevens	geen gegevens
Qinglei Zuo	Chief Commercial Officer	3.8yrs	geen gegevens	geen gegevens
NA NA	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Tingchan Chen	Joint Company Secretary	1.2yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

45.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1477 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ye Liu	CEO & Executive Director	6yrs	CN¥5.94m	4.15% HK$ 176.0m
Zhaopeng Hu	Chief Development Officer & Executive Director	4.6yrs	CN¥2.21m	0.46% HK$ 19.5m
Yanling Cao	Non-Executive Director	5.4yrs	geen gegevens	geen gegevens
Ting Yuk Wu	Independent Non-Executive Director	4.4yrs	CN¥720.00k	geen gegevens
Lian Yong Chen	Non-Executive Chairman of the Board	6.5yrs	geen gegevens	10.81% HK$ 458.5m
Zhenyu Zhang	Independent Non-Executive Director	2.6yrs	CN¥135.00k	geen gegevens
Yiran Huang	Independent Non-Executive Director	4.4yrs	CN¥180.00k	geen gegevens
Wei Li	Non-Executive Director	6.6yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1477 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Ocumension Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Ocumension Therapeutics Voluntary Announcement primary Clinical Endpoint Achieved in the Phase III clinical Trial of OT-1001

Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Ocumension Therapeutics Announces First Patient Enrolled in the Clinical Trial of self-Developed Class I New Drug OT-202 in China

Consensus forecasts updated

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

First half 2021 earnings released: CN¥0.12 loss per share (vs CN¥27.36 loss in 1H 2020)

Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical Trial OT-502 (DEXYCU®) in China